Hans-joachim J. Schmoll

Ernst Grube Str. 40
Halle, NI 06120, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 95 publications

Sex differences in efficacy and toxicity of first-line treatment of metastatic colorectal cancer: An analysis of 18,041 patients in the ARCAD CRC database.

Sex differences in efficacy and toxicity of first-line treatment of metastatic colorectal cancer: An analysis of 18,041 patients in the ARCAD CRC database.

Journal: European journal of cancer (Oxford, England : 1990)

Published: February 12, 2026

The Definition of Cure in Colon Cancer: A Pooled Analysis of 15 Randomized Clinical Trials.

The Definition of Cure in Colon Cancer: A Pooled Analysis of 15 Randomized Clinical Trials.

Journal: JAMA oncology

Published: October 02, 2025

Chronological survival improvement over time with oxaliplatin-based chemotherapy plus targeted agents in metastatic colorectal cancer: An ARCAD database study.

Chronological survival improvement over time with oxaliplatin-based chemotherapy plus targeted agents in metastatic colorectal cancer: An ARCAD database study.

Journal: European journal of cancer (Oxford, England : 1990)

Published: August 20, 2025

Assessment of the Addition of Oxaliplatin to Fluoropyrimidine-Based Adjuvant Chemotherapy in Patients With High-Risk Stage II Colon Cancer: An ACCENT Pooled Analysis.

Assessment of the Addition of Oxaliplatin to Fluoropyrimidine-Based Adjuvant Chemotherapy in Patients With High-Risk Stage II Colon Cancer: An ACCENT Pooled Analysis.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: September 04, 2024

Predicting Benefit From FOLFOXIRI Plus Bevacizumab in Patients With Metastatic Colorectal Cancer.

Predicting Benefit From FOLFOXIRI Plus Bevacizumab in Patients With Metastatic Colorectal Cancer.

Journal: JCO clinical cancer informatics

Published: July 17, 2024

Efficacy and quality of life for FOLFOX/bevacizumab +/- irinotecan in first-line metastatic colorectal cancer-final results of the AIO CHARTA trial.

Efficacy and quality of life for FOLFOX/bevacizumab +/- irinotecan in first-line metastatic colorectal cancer-final results of the AIO CHARTA trial.

Journal: British journal of cancer

Published: July 14, 2023

Evaluation of Intratumoral Response Heterogeneity in Metastatic Colorectal Cancer and Its Impact on Patient Overall Survival: Findings from 10,551 Patients in the ARCAD Database.

Evaluation of Intratumoral Response Heterogeneity in Metastatic Colorectal Cancer and Its Impact on Patient Overall Survival: Findings from 10,551 Patients in the ARCAD Database.

Journal: Cancers

Published: June 16, 2023

A systematic review of clinical trials of treatment regimens in HER2-amplified metastatic colorectal cancer.

A systematic review of clinical trials of treatment regimens in HER2-amplified metastatic colorectal cancer.

Journal: Expert review of anticancer therapy

Published: May 01, 2023

Clinical and exploratory biomarker findings from the MODUL trial (Cohorts 1, 3 and 4) of biomarker-driven maintenance therapy for metastatic colorectal cancer.

Clinical and exploratory biomarker findings from the MODUL trial (Cohorts 1, 3 and 4) of biomarker-driven maintenance therapy for metastatic colorectal cancer.

Journal: European journal of cancer (Oxford, England : 1990)

Published: November 10, 2022

Clinical Trial Endpoints in Metastatic Cancer: Using Individual Participant Data to Inform Future Trials Methodology.

Clinical Trial Endpoints in Metastatic Cancer: Using Individual Participant Data to Inform Future Trials Methodology.

Journal: Journal of the National Cancer Institute

Published: July 05, 2021

Metastatic Colorectal Cancer Outcomes by Age Among ARCAD First- and Second-Line Clinical Trials.

Metastatic Colorectal Cancer Outcomes by Age Among ARCAD First- and Second-Line Clinical Trials.

Journal: JNCI cancer spectrum

Published: May 28, 2021

Reevaluating Disease-Free Survival as an Endpoint vs Overall Survival in Stage III Adjuvant Colon Cancer Trials.

Reevaluating Disease-Free Survival as an Endpoint vs Overall Survival in Stage III Adjuvant Colon Cancer Trials.

Journal: Journal of the National Cancer Institute

Published: April 07, 2021

Showing 1-12 of 95

Last Updated: 09/26/2026